CATX
AMEX
$2.93
Perspective Therapeutics Inc (CATX)
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.
Sector:
Healthcare
Industry:
Medical Devices
Buy
Target: $12.93 (+342.05%)
Market Cap
$367M
EPS 5Y CAGR
+89.93%
FCF 5Y CAGR
+103.83%
Free Cash Flow Yield
-29.28%
Price Chart
Valuation
Market Cap$367M
Forward P/E25.71
P/S594.22
P/B1.00
Profitability
Gross Profit (TTM)-$91M
EBITDA-$116M
Operating Margin-37212%
EPS-$1.37
Financial Health
Debt-to-Equity0.5%
Free Cash Flow Yield-29.28%
Growth & Risk
EPS 5Y CAGR+89.93%
FCF 5Y CAGR+103.83%
Beta (5Y)1.52
Sharpe Ratio0.14